The new ATU programme may support more efficient use of healthcare spending but could it mean fewer patients receive early access to treatments? Here, experts from Charles River Associates discuss the new ATU programme reforms and how they could impact pharma.
What is the current situation?
The temporary authorisation for use (Autorisation Temporaire d’Utilisation, ATU) programme in France is intended to provide early access to medicines for patients with a severe or rare disease with high unmet need and for which no authorised therapeutic alternatives available. Since its implementation in 1994, the ATU has been a key consideration for manufacturers seeking to minimise access delays and bring life-changing treatments to patients as early as possible. While the ATU system was initially designed to ensure access to new therapies for human immunodeficiency viruses (HIV), it has progressively expanded to cover all therapy areas, including oncology, haematology and rare diseases.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Access to pre-authorised medications in France may be granted through the nominative ATU (nATU) or cohort ATU (cATU). The nATU is issued for a single, named patient at the request of the prescribing physician. However, the more frequently used cATU is issued at the request of the manufacturer to a group of patients treated and monitored according to a well-defined protocol. There are always requirements for follow-up and data collection and manufacturers must commit to submit a market authorisation application within a pre-determined period. The cATU programme offers several benefits to manufacturers. Firstly, there is the option to set a price freely, much like the one-year “free price” during the benefit assessment in Germany. This helps establish a price benchmark ahead of formal price negotiations. In addition, the cATU supports the claim of high unmet need, often leading to a higher rate on the improvement of medical benefit (Amelioration du Service Médical Rendu, ASMR) which is beneficial for price negotiations. Furthermore, the manufacturer can potentially collect and leverage aggregated real-world evidence (RWE) data from French patients to include in the submission dossier and support the health technology assessment (HTA).
As a result of expanded use of cATUs over recent years, funding of new products through the system has grown to over €1 billion a year.1 In 2020, the French ministry of health proposed several reforms to the ATU system, the full implications of which remain unclear. But it is important to question if the reforms will improve early access for patients or make the situation more challenging.
What has changed?
The most recent French Social Security law of 14th December 2020 (Article 78- La Loi de financement de la sécurité sociale, FSSL) for the healthcare plan of 2021, implemented changes to the existing ATU system. The ATU programme, previously divided into six systems, has now been grouped into two: an early access authorisation programme (Accès précoce aux médicaments, EAP) which includes the cATU and a compassionate access programme (Accès compassionnel aux médicaments, CAP) which includes nATU, among others. The reforms will come into force no later than 1st July 2021 and ATUs with an expiry date after this date will not be eligible for renewal and will have to reapply.2
What is new about the EAP?
Manufacturers will now be required to make all EAP requests to the HTA body (Haute Autorité de Santé, HAS), not to the regulatory agency (Agence nationale de sécurité du médicament et des produits de santé, ANSM).2 While the ANSM will still be consulted, the decision-making power will lie with HAS, giving it access to clinical evidence prior to European Medicines Agency (EMA) approval and dossier submission. As the EAP data will need to be collected using a standardised approach, it is possible that HAS will consider these data in the clinical assessment. If so, this could lead to faster HTA review by the transparency committee (Commission de la Transparence, TC) and quicker time to reimbursement.
Another novel aspect of the reforms is the introduction of the presumption of innovation for the products, compared with the most clinically relevant comparator.3 It is currently unclear how HAS will define and quantify innovation, but there is a risk that this may negatively impact the number of products eligible for the EAP programme, particularly for products with more immature data. In addition, it is unclear whether HAS will continue to consider unmet need as part of the decision. For example, does a small magnitude of improvement in an otherwise untreated population with poor outcomes warrant early access, or will it be reserved for those products showing ‘significant’ benefit, regardless of unmet need? As the TC considers the level of unmet need during the clinical evaluation, it is possible that this will continue to be taken into account for early access programmes.
The manufacturer is still able to set a free price for these products but the mechanism for payback has changed. Specifically, if the final negotiated price is lower than the price set during the EAP programme, manufacturers will be required to pay back the difference.2 Under the new law, the payback payment will be based on actual revenues, rather than pre-paid based on forecasted revenues.
What is new about the CAP?
Under the reforms, the bar for evidence requirements is now higher, both in terms of the quality and quantity of evidence needed to demonstrate innovation”
Like the EAP requirements, the CAP criteria are now stricter as the manufacturer needs to demonstrate that the efficacy and safety of a given product is ‘’strongly presumed,’’ as opposed to ‘’considered’’ to be favourable under the old system.2,3 The manufacturer must not only follow a well-established clinical protocol and collect data during the period required by HAS, but also needs to demonstrate that trials have started. A limit on the total number of CAP requests for the nATUs per product has been introduced and, if reached, the manufacturer has the option to apply for an EAP. This reform could lead to a lower number of patients able to benefit from a CAP, given the introduction of the new limit on nATUs. While the price of nATUs will remain confidential, it will now be set by the authorities and not by the manufacturer.4
What does this mean for pharma?
Under the reforms, the bar for evidence requirements is now higher, both in terms of the quality and quantity of evidence needed to demonstrate innovation. It is possible this could lead to fewer EAP products approved compared with the previous cATU system and subsequently to fewer patients having access to potentially much-needed treatments.
While it remains to be seen how the EAP and CAP systems will impact pricing and market access in the future, the French authorities seem to have increased the hurdles to early access. There appears little benefit to manufacturers, except potentially the ability to leverage RWE data to help secure faster time to reimbursement. They may also face lower sales opportunities under the CAP programme versus the previous nATU.
Under the reforms, fewer products are likely to be approved compared with the previous ATU system. For many years, France has claimed its early access programme is the most generous and fairest for patients in Europe. Will this still be the case in the future?
Cécile Matthews, Vice President at Charles River Associates, contactable at [email protected]
Ioanna Stefani, Senior Associate at Charles River Associates, contactable at [email protected]
Paula Urruticoechea, Consulting Associate at Charles River Associates, contactable at [email protected]
The views expressed herein are the views and opinions of the authors and do not reflect or represent the views of Charles River Associates (CRA) or any of the organizations with which the authors are affiliated.
About CRA and the Life Sciences Practice
CRA is a leading global consulting firm that offers strategy, financial and economic consulting services to industry, government and financial clients. The Life Sciences Practice works with leading biotech, medical device and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations.
LOI n° 2020-1576 du 14 décembre 2020 de financement de la sécurité sociale pour 2021 (1) [Internet]. Legifrance.gouv.fr. 2020. Available from: https://www.legifrance.gouv.fr/jorf/id/…
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.